CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Dexamethasone Sodium Phosphate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2019-02-08. Latest FDA row update: 2026-10-05.
FDA lists 19 package records, with companies: Eugia US LLC, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Mylan Institutional LLC, Mylan Institutional, a Viatris Company, Somerset Therapeutics, LLC. Package NDCs: 0641-0367-25, 0641-6145-25, 0641-6146-25, 55150-304-25, 63323-165-01, 63323-165-05, 63323-165-30, 63323-506-01, 63323-516-10, 67457-420-10, 67457-421-30, 67457-422-54, 67457-423-12, 70069-021-25, 70069-025-10, 76045-0210-10, 76045-0212-10, 76045-210-10, 76045-212-10.
FDA shortage reason: Demand increase for the drug
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Eugia US LLC | 55150-304-25 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25) | Available | 2026-10-02 |
| Fresenius Kabi USA, LLC | 63323-506-01 | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-516-10 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 76045-0212-10 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10) | Limited Availability | 2026-09-15 |
| Fresenius Kabi USA, LLC | 76045-212-10 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10) | Limited Availability | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-165-01 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-165-05 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-165-30 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 76045-0210-10 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 76045-210-10 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10) | Available | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0641-0367-25 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6145-25 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25) | Available | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0641-6146-25 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25) | Available | 2026-09-18 |
| Mylan Institutional, a Viatris Company | 67457-420-10 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) | Available | 2026-10-05 |
| Mylan Institutional, a Viatris Company | 67457-421-30 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30) | Available | 2026-10-05 |
| Mylan Institutional, a Viatris Company | 67457-422-54 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54) | Available | 2026-10-05 |
| Mylan Institutional, a Viatris Company | 67457-423-12 | Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12) | Available | 2026-10-05 |
| Somerset Therapeutics, LLC | 70069-021-25 | Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25) | Available | 2026-09-11 |
| Somerset Therapeutics, LLC | 70069-025-10 | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10) | Available | 2026-09-11 |
Source facts
Grouped generic ingredient: Dexamethasone Sodium Phosphate Injection · 19 package records
Therapeutic categories: Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology
Dosage forms: Injection
Routes: INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.